IGeneX

Reference Guide

IGeneX

Order, track, and receive results from 30+ labs in one place.

About the Lab

Popular Tests

Quality Control

About the Lab

IGeneX Inc. offers accurate, reliable, comprehensive, and rapid testing for tick-borne illnesses, relapsing fever, and Lyme disease, and leads in research and testing development for Lyme disease and tick-borne illnesses assessment globally.

Located in Milpitas, California, IGeneX was initiated in 1991 by the leading pioneer in Lyme disease. They are focused on research and development to improve diagnostic testing methods and specificity and to increase capabilities to detect more tick-borne pathogens.

IGeneX Inc. is committed to educating patients and practitioners and facilitating collaboration with clinical practitioners to improve access to diagnosis and management of Lyme and tick-borne illnesses.

IGeneX Inc. ensures quality laboratory diagnostic testing through certification, licensing by the required agencies, and developing internal testing criteria to ensure accuracy and specificity.

IGeneX Inc. is led by experts with knowledge and research on tick-borne illnesses and Lyme disease, diagnostic testing development, and laboratory management.

About the Lab

iGenex offers testing for lyme disease, relapsing fever, and other tick-borne illnesses.

Popular Tests by

IGeneX

Lyme ImmunoBlot IgG

Serum

The Lyme ImmunoBlot IgG is a qualitative assay that detects IgG antibodies to B. burgdorferi strains and species. IgG antibodies are typically present a few months following initial infection.

Lyme ImmunoBlot IgM

Serum

The Lyme ImmunoBlot IgM is a qualitative assay that detects IgM antibodies to B. burgdorferi strains and species. The IgM ImmunoBlot may be positive as early as 1 week after a tick bite and will usually remain positive for six to eight weeks after initial exposure.

Lyme Serology IgG/IgM

Serum

The IgG/IgM Antibody Serology test indicates the presence of both IgG and IgM antibodies to B. burgdorferi. Unlike IgM antibodies, which are present shortly after infection takes place, IgG antibodies often persist long after symptoms have disappeared. The presence of antibodies indicate exposure to Lyme–causing Borrelia, not active disease. A positive or equivocal test must be confirmed by both IgG and IgM ImmunoBlots. This test is recommended at least four weeks after exposure.

Broad Coverage Lyme Ab Assay

Serum

The Lyme Broad Coverage Antibody (BCA) Assay is a qualitative test designed to detect IgM and IgG antibodies to Lyme Borreliae group–specific antigens in human serum. The sensitivity of the Lyme BCA Assay is 90%, and the specificity is 97%.

Lyme IgG/IgM/IgA Screen

Serum

This test detects antibodies (IgG, IgM, IgA) against B. burgdorferi. Seroconversion usually occurs 2–3 weeks after infection and may remain elevated in cases of persistent disease. A positive or equivocal result is preliminary and should be confirmed with IgG and IgM Western Blot.

Lyme ImmunoBlot Panel 1 (IB1)

Serum

This panel is designed to detect Lyme disease. It combines three tests: Lyme IgG/IgM/IgA Screen, Lyme ImmunoBlot IgM, and Lyme ImmunoBlot IgG.

Lyme ImmunoBlot IgG + IgM

Serum

The Lyme ImmunoBlot is a qualitative assay that detects antibodies to B. burgdorferi strains and species. This test includes IgG and IgM antibodies. IgM antibodies may be present as early as 1 week after a tick bite and will usually remain present for six to eight weeks after initial exposure. IgG antibodies are typically present a few months following initial infection.

Babesia FISH

Whole Blood

The Babesia FISH assay is designed for qualitative detection of ribosomal RNA of Babesia parasites directly in a blood smear. The test’s highest degree of specificity is provided by nucleic acid probes, which bind to RNA sequences of the Babesia. This test detects all species of Babesia.

Lyme IGXSpot

Whole Blood

The IgXSpot test is an enzyme–linked immunospot assay that detects human T cells reactive to Borrelia/pathogen–specific antigens in vitro. It is recommended for detection of very early and/or late Borrelia/pathogen infection and in seronegative patient’s whole blood samples. When combined with Lyme ImmunoBlot tests, this test provides information on the full spectrum of a patient’s immune response to infection and stage of disease.

Tick Borne Disease Panel 7 (TBD7)

Urine

This panel is designed to detect multiple tickborne diseases. It combines 7 urine tests to detect Lyme Disease, TBRF, Bartonellosis, Babesiosis, Anaplasmosis, and Ehrlichiosis.